Scope Fluidics S.A.

Warsaw Stock Exchange SCP.WA

Scope Fluidics S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD -59.40 M

Scope Fluidics S.A. Net Cash Used Provided By Financing Activities is USD -59.40 M for the year ending December 31, 2023, a -759.44% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • Scope Fluidics S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD -6.91 M, a -256.02% change year over year.
  • Scope Fluidics S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 4.43 M, a -30.69% change year over year.
  • Scope Fluidics S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 6.39 M, a 18.93% change year over year.
  • Scope Fluidics S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 5.37 M, a 1,907.46% change year over year.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
SV Wall Street
Warsaw Stock Exchange: SCP.WA

Scope Fluidics S.A.

CEO Mr. Piotr Garstecki
IPO Date Aug. 1, 2017
Location Poland
Headquarters 9th floor
Employees 40
Sector Healthcare
Industries
Biotechnology Medical Instruments
Description

Scope Fluidics S.A., a biotechnology company, engages in the designing and developing projects based on microfluidic technologies in medical diagnostics and healthcare. It offers BacterOMIC, an antibiotic susceptibility testing. The company was founded in 2010 and is based in Warsaw, Poland.

Similar companies

COG.WA

Cognor Holding S.A.

USD 1.57

-0.33%

BMC.WA

Bumech S.A.

USD 2.36

-1.10%

StockViz Staff

February 6, 2025

Any question? Send us an email